Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(19 sites)
France
Brest University Hospital Centre, Brest, Brest Centre Régional de Lutte Contre le Cancer Institut Bergonié (Bordeaux), Bordeaux, Cedex Centre Oscar Lambret, Lille, Lille Hôpital Edouard Herriot (Hospices Civils Lyon), Lyon, Lyon Institut de Cancérologie de l'Ouest (Angers/Nantes), Nantes, Nantes Last updated February 2026